Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 4/20 | 0.39 |
| ▸ | PIK3R2 | O00459 | 13/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 10/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1694990 | 0.92 | PTGES (0.38) | PTGESPIK3R2PIK3CDCHRM1PIK3CG | |
| SCHEMBL1695024 | 0.87 | CNR2 (0.40) | PTGES | |
| SCHEMBL10146917 | 0.85 | AURKA (0.40) | PIK3R2PIK3CDPIK3CGAURKARPS6KB1 | |
| SCHEMBL10147624 | 0.84 | PIK3R2 (0.42) | PIK3R2PIK3CDPIK3CG | |
| SCHEMBL14815712 | 0.83 | PIK3R2 (0.46) | PIK3R2PIK3CDPIK3CG | |
| SCHEMBL1694986 | 0.83 | PIK3R2 (0.46) | PIK3R2PIK3CDPIK3CG | |
| SCHEMBL1695297 | 0.82 | ADORA2A (0.39) | PTGESPIK3R2PIK3CDPIK3CGMAP4K4 | |
| SCHEMBL1695362 | 0.81 | PIK3R2 (0.41) | PIK3R2PIK3CDPIK3CGMAP4K4 | |
| SCHEMBL1695135 | 0.81 | PIK3R2 (0.43) | PIK3R2PIK3CDPIK3CG | |
| SCHEMBL1695343 | 0.80 | PIK3R2 (0.41) | PIK3R2PIK3CDPIK3CGMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012003274-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |